WO1999025347A3 - Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction - Google Patents

Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction Download PDF

Info

Publication number
WO1999025347A3
WO1999025347A3 PCT/DK1998/000490 DK9800490W WO9925347A3 WO 1999025347 A3 WO1999025347 A3 WO 1999025347A3 DK 9800490 W DK9800490 W DK 9800490W WO 9925347 A3 WO9925347 A3 WO 9925347A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
chemical compounds
immune dysfunction
ion channel
blocking activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK1998/000490
Other languages
French (fr)
Other versions
WO1999025347A2 (en
Inventor
Soeren-Peter Olesen
Bo Skaaning Jensen
Tino Dyhring Joergensen
Dorte Stroebaek
Palle Christophersen
Niels Oedum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Priority to AU12245/99A priority Critical patent/AU1224599A/en
Priority to EP98955387A priority patent/EP1052990A2/en
Publication of WO1999025347A2 publication Critical patent/WO1999025347A2/en
Publication of WO1999025347A3 publication Critical patent/WO1999025347A3/en
Priority to US09/550,645 priority patent/US6545028B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to chemical compounds having inhibitory activity on an intermediate conductance Ca2+ activated potassium channel (IK¿Ca?), and the use of such compounds for the treatment or alleviation of diseases or conditions relating to immune dysfunction. Moreover, the invention relates to a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca?2+¿ activated potassium channel (IK¿Ca?).
PCT/DK1998/000490 1997-11-14 1998-11-13 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction Ceased WO1999025347A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU12245/99A AU1224599A (en) 1997-11-14 1998-11-13 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
EP98955387A EP1052990A2 (en) 1997-11-14 1998-11-13 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
US09/550,645 US6545028B2 (en) 1997-11-14 2000-04-14 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK1298/97 1997-11-14
DK129897 1997-11-14
DK38698 1998-03-19
DK0386/98 1998-03-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/550,645 Continuation US6545028B2 (en) 1997-11-14 2000-04-14 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Publications (2)

Publication Number Publication Date
WO1999025347A2 WO1999025347A2 (en) 1999-05-27
WO1999025347A3 true WO1999025347A3 (en) 1999-07-29

Family

ID=26063900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1998/000490 Ceased WO1999025347A2 (en) 1997-11-14 1998-11-13 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Country Status (4)

Country Link
US (1) US6545028B2 (en)
EP (1) EP1052990A2 (en)
AU (1) AU1224599A (en)
WO (1) WO1999025347A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
WO1997034589A1 (en) 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
ATE366260T1 (en) 1996-09-11 2007-07-15 Univ Oregon Health Sciences LOW AND MEDIUM CONDUCTIVITY CALCIUM-ACTIVATED POTASSIUM CHANNELS AND THEIR USES.
EP1187610A2 (en) 1999-05-12 2002-03-20 Neurosearch A/S Use of ion channel modulating agents
WO2000069439A1 (en) * 1999-05-12 2000-11-23 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
US6803375B1 (en) * 2000-01-06 2004-10-12 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
CA2433041A1 (en) * 2000-12-28 2002-07-11 Switch Biotech Aktiengesellschaft Use of intermediate-conductance potassium channels and modulators for diagnosing and treating diseases involving disturbed keratinocyte activiyty
AU2003259028A1 (en) * 2002-06-10 2003-12-22 Combinatorx, Incorporated Combinations for the treatment of rheumatoid arthritis
CA2538991A1 (en) 2003-09-18 2005-03-31 Children's Medical Center Corporation Treatment of severe distal colitis
EP1968563A4 (en) * 2005-12-20 2010-05-19 Icagen Inc Treatment methods using triaryl methane compounds
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
EP1800673A3 (en) * 2005-12-23 2007-08-15 Canadian Blood Services Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction
US20100261765A1 (en) * 2007-12-14 2010-10-14 Brandish Philip E Mineralocorticoid receptor modulators
US8932154B2 (en) 2007-12-28 2015-01-13 Taylor Made Golf Company, Inc. Golf ball with softer feel and high iron spin
CN101575314B (en) * 2009-06-25 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 Dihydropyridine compounds and application thereof on preparing drugs for curing and/or preventing virus diseases
US20130281504A1 (en) * 2010-06-28 2013-10-24 The Regents Of The University Of California Reduction of Microglia-Mediated Neurotoxicity by KCa3.1 Inhibition
WO2014159343A1 (en) * 2013-03-14 2014-10-02 Celtaxsys, Inc. Method of stimulating immune cell migration
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives
WO2022115043A1 (en) * 2020-11-30 2022-06-02 Nanyang Technological University POTENT AND SELECTIVE INHIBITORS OF THE CALCIUM-ACTIVATED POTASSIUM CHANNEL, KCa3.1, FOR USE AS PLATFORM THERAPEUTICS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435409A (en) * 1981-12-10 1984-03-06 Usv Pharmaceutical Corporation Method of stimulating production of IgM antibodies
EP0531598A1 (en) * 1988-01-21 1993-03-17 Alter, S.A. 1,4-Dihydropyridines with paf-antagonistic activity
JPH08225450A (en) * 1995-02-21 1996-09-03 Green Cross Corp:The Lipid oxidation inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) * 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
DE2117571C3 (en) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Asymmetrical 1,4-dihydropyridine-33-dicarboxylic acid esters, process for their preparation and their use as pharmaceuticals
US4952594A (en) * 1973-06-18 1990-08-28 Mercer James B Reagents and method for therapeutic treatment of multiple sclerosis
JPS6048486B2 (en) * 1976-01-01 1985-10-28 木場 常義 antirheumatic agent
US4267169A (en) * 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
US5670113A (en) 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
AU1839695A (en) 1994-02-08 1995-08-29 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Dna encoding atp-sensitive potassium channel proteins and uses thereof
EP0781128B1 (en) 1994-09-16 2005-11-23 Children's Medical Center Corporation Clotrimazole metabolites in the treatment of sickle cell disease
WO1997034589A1 (en) 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435409A (en) * 1981-12-10 1984-03-06 Usv Pharmaceutical Corporation Method of stimulating production of IgM antibodies
EP0531598A1 (en) * 1988-01-21 1993-03-17 Alter, S.A. 1,4-Dihydropyridines with paf-antagonistic activity
JPH08225450A (en) * 1995-02-21 1996-09-03 Green Cross Corp:The Lipid oxidation inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9645, Derwent World Patents Index; Class B03, AN 96-450923, XP002100106 *
RADER R K ET AL: "T cell activation is regulated by voltage-dependent and calcium-activated potassium channels.", JOURNAL OF IMMUNOLOGY, (1996 FEB 15) 156 (4) 1425-30. JOURNAL CODE: IFB. ISSN: 0022-1767., United States, XP002100103 *
RANDRIAMAMPITA C ET AL: "Nitrendipine -induced inhibition of calcium influx in a human T - cell clone: role of cell depolarization.", CELL CALCIUM, (1991 APR) 12 (4) 313-23. JOURNAL CODE: CQE. ISSN: 0143-4160., SCOTLAND: United Kingdom, XP002100105 *
VERHEUGEN ET AL.: "Enhancement of calcium signaling and proliferation responses in activated human lymphocytes", CELL CALCIUM, vol. 21, no. 1, 1997, pages 1 - 17, XP002100102 *
VOLL, R. ET AL: "Nitrendipine inhibits proliferation and cytokine secretion in human T cell clones.", IMMUNOBIOLOGY, (1994) VOL. 191, NO. 2-3, PP. 138-139. MEETING INFO.: XXVTH MEETING OF THE SOCIETY OF IMMUNOLOGY KONSTANZ, GERMANY SEPTEMBER 21-24, 1994 ISSN: 0171-2985., XP002100104 *

Also Published As

Publication number Publication date
US20020119989A1 (en) 2002-08-29
WO1999025347A2 (en) 1999-05-27
US6545028B2 (en) 2003-04-08
AU1224599A (en) 1999-06-07
EP1052990A2 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
WO1999025347A3 (en) Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
ZA967911B (en) Synergistically active herbicidal mixtures.
ZA961291B (en) Naphthyl compounds, intermediates, compositions, and methods.
ZA200007641B (en) Treatment of airborne allergens.
ZA966584B (en) Blooming type, hard surface cleaning and/or disinfecting compositions.
BG102690A (en) Il-8 receptor antagonists
ZA977948B (en) Process for the control of weeds.
EP0846466A3 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
EP0935963A3 (en) The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders
CA2381770A1 (en) Human ctla-4 antibodies and their uses
WO2002092122A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2000028999A3 (en) Methods of treating tardive dyskinesia and other movement disorders
MD1745B2 (en) 4,5-dimethyl-N-2-propenyl-2-(trimethylsilyl)-3-thiophencarboxamide, fungicidal composition on base thereof and method of plants diseases control
ZA9610543B (en) Compounds and compositions for reducing blood glucose and/or inhibiting the activity of CGRP.
ZA969876B (en) Pest trap.
ATE235819T1 (en) SYNERGISTIC HERBICIDE MIXTURES CONTAINING CYCLOHEXENONE OXIMETHER
GR1002768B (en) Poisoned baits for use against pests
WO1999007729A3 (en) Peptides having potassium channel opener activity
DK0840548T3 (en) Synergistic, herbicidal composition and method of preparation thereof
BG102667A (en) Diosgenine-containing composition
EP0876598A4 (en) 1.2 IMPROVED CHIMILUMINESCENT DIOXETANES
AU4537300A (en) Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
EP0811688A3 (en) Staphylococcus aureus RNase P
IL139303A0 (en) Treatment of arthritis and other similar conditions
ZA985079B (en) Fixation or separation of ions particularly of Pb by per (3,6-anhydro)cyclodextrin derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998955387

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09550645

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998955387

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998955387

Country of ref document: EP